Multimodal deep learning model for prediction of breast cancer recurrence risk and correlation with oncotype DX. [PDF]
Zhang R +7 more
europepmc +1 more source
This study presents an injectable hydrogel that responds to Pseudomonas aeruginosa infection by releasing a dual‐phage cocktail on demand. The system degrades selectively in infected wounds, enhances phage localization and stability, and shows potent antibiofilm activity and biocompatibility in an ex vivo human skin model—offering a promising strategy ...
Siyuan Tao +9 more
wiley +1 more source
Predictive value of preoperative CA19-9 and neutrophil-to-lymphocyte ratio for early recurrence in patients with resected pancreatic ductal adenocarcinoma. [PDF]
Ye WK +6 more
europepmc +1 more source
A facile and effective method to boost NIR light induced photocatalysis based on nontoxic NIR emissive carbon dots (nir‐CDs) via Self‐trapped excitons, showing that both O2− • and •OH can be generated from nir‐CDs under NIR laser irradiation. Abstract Near‐infrared (NIR) light‐triggered photocatalytic therapy remains a critical challenge in efficient ...
Qingcheng Wang +8 more
wiley +1 more source
Prognostic impact of non-clear cell histology on recurrence and cancer-free survival in renal cell carcinoma: a time-to-event analysis. [PDF]
Tayeb W +8 more
europepmc +1 more source
DENTA: A Dual Enzymatic Nanoagent for Self‐Activating Tooth Whitening and Biofilm Disruption
The nanoapatite with dual enzymes (DENTA) accumulates in dentinal tubules, reducing hypersensitivity caused by dental nerve exposure and facilitating continuous ROS generation through salivary glucose for effective, long‐term whitening. The dentin structures remain non‐destructive due to the low concentration of ROS, demonstrating excellent cell ...
Junseok Kim +13 more
wiley +1 more source
27-Day Recurrence of Cosmic-Ray Intensity at the Minimum Solar Activity
Masahiro Kodama
openalex +2 more sources
Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma. [PDF]
Versluis JM +15 more
europepmc +1 more source

